+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Unaltered perception of dyspnoea during treatment with long-acting beta2-agonists



Unaltered perception of dyspnoea during treatment with long-acting beta2-agonists



European Respiratory Journal 18(2): 269-271



There is the possibility that during treatment with inhaled long-acting beta2-agonists that a loss of perception of dyspnoea might occur and that the forced expiratory volume in one second (FEV1) might fall precipitously during bronchial provocation. This study investigated these possibilities during methacholine provocation, continued until there was > or =30% fall in FEV1, mimicking a moderate asthma attack. Nineteen asthmatic patients were asked to score their dyspnoea as a Borg score during provocation with methacholine. One hour prior to this provocation, the patients used the last morning dose of 14 days treatment with either formoterol (twice daily 24 microg by Turbuhaler), salmeterol (twice daily 100 microg by Diskhaler) and placebo in a double-blind, randomized, double-dummy, cross-over design. The perception of dyspnoea, expressed as the Borg score divided by the change in FEV1 at > or =30% fall in FEV1, was similar on the three test days at 0.067, 0.076 and 0.074%(-1) after formoterol, salmeterol and placebo treatment, respectively (p=0.16). The slope of the methacholine dose response curve did not differ (p=0.52). In conclusion, no suggestion was found for an abnormal perception of dyspnoea or an exaggerated fall in forced expiratory volume in one second during provocation with methacholine under long-acting beta2-agonist treatment.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011611050

Download citation: RISBibTeXText

PMID: 11529283


Related references

Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma. European Respiratory Journal 19(2): 240-245, 2002

Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists. Respiratory Medicine 96(3): 155-162, 2002

Potential masking effect on dyspnoea perception by short- and long-acting 2-agonists in asthma. European Respiratory Journal 19(2): 240-245, 2002

Do long-acting beta2 agonists impair the effect of short-acting beta2 agonists in some patients?. American Family Physician 84(10): 1080; Author Reply 1080 1085, 2011

Part IV: Genetic variations in beta2-adrenergic receptors: long-acting and short-acting beta2-agonists and therapeutic response. Current Medical Research and Opinion 23(Suppl. 3): S29-S36, 2007

Safety of long-acting beta2-agonists in the treatment of asthma. Therapeutic Advances in Respiratory Disease 1(1): 35-46, 2007

Are long-acting beta2-agonists safe in the treatment of asthma?. Polskie Archiwum Medycyny Wewnetrznej 118(9): 460-461, 2008

Long-acting beta2-agonists in the treatment of acute exacerbations of COPD. Clinical Drug Investigation 22(6): 369-376, 2002

Beta2-Adrenoceptor polymorphism and bronchoprotective sensitivity with regular short and long-acting beta2-agonists. European Respiratory Journal 12(Suppl. 28): 372S, 1998

Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database of Systematic Reviews 2007(3): Cd001281, 2007

The effect of polymorphisms of beta2 adrenoceptors on response to long-acting beta2 agonists in Iranian asthmatic patients. Iranian Journal of Allergy Asthma and Immunology 12(4): 383-390, 2013

Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 3: Cd012930, 2019

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews 2015(6): Cd011438, 2015

Desensitisation of beta2-adrenoceptor-mediated responses by long-acting beta2-agonists in human lung mast cells. British Journal of Pharmacology 135(Proceedings Suppl.): 266P, 2002

Long-acting beta2-agonists versus long-acting muscarinic antagonists in patients with stable COPD: A systematic review and meta-analysis of randomized controlled trials. Respirology 22(7): 1313-1319, 2017